Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 7/20 | 0.45 |
| ▸ | SLC2A3 | P11169 | 7/20 | 0.45 |
| ▸ | SLC2A2 | P11168 | 6/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PDE9A | O76083 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30120627 | 1.00 | SLC2A1 (0.45) | SLC2A1SLC2A3SLC2A2CYP17A1CYP1A2 | |
| SCHEMBL23723532 | 0.84 | GRM5 (0.49) | SLC2A1SLC2A3SLC2A2CYP1A2NPC1 | |
| SCHEMBL23723660 | 0.78 | KMT2A (0.47) | CYP1A2NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL23723775 | 0.78 | SMN1; SMN2 (0.51) | NPC1RAB9AMAPTALDH1A1KDM4E | |
| SCHEMBL30120729 | 0.78 | SMN1; SMN2 (0.50) | SLC2A1SLC2A3SLC2A2CYP17A1CYP1A2 | |
| SCHEMBL23723574 | 0.78 | SMN1; SMN2 (0.50) | SLC2A1SLC2A3SLC2A2CYP17A1CYP1A2 | |
| SCHEMBL6205196 | 0.76 | SLC2A1 (0.65) | SLC2A1SLC2A3SLC2A2CYP17A1CYP1A2 | |
| SCHEMBL30132099 | 0.76 | PDE9A (0.38) | SLC2A1SLC2A3SLC2A2CYP17A1CYP1A2 | |
| SCHEMBL23723650 | 0.76 | PDE9A (0.38) | SLC2A1SLC2A3SLC2A2CYP17A1CYP1A2 | |
| SCHEMBL23723527 | 0.74 | SMN1; SMN2 (0.51) | CYP1A2NPC1RAB9AL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| EP-4100015-A1 | COMBINATION THERAPY FOR TREATING MPS1 | Gain Therapeutics SA (CH) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021156774-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021156774-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | IDUA, MAN2B1, GBA1 | SLC2A1 946/4885SLC2A3 1007/4885SLC2A2 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.